 |
|
|
| |
NS5A resistance patterns and treatment outcomes in DAA-naïve genotype 1a (GT1a) chronic hepatitis C patients with and without baseline resistance-associated substitutions (RASs)
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Julia Dietz1, Johannes Vermehren1, Simone Susser1, Kai-Henrik Peiffer1, Tania Welzel1, Karsten Wursthorn2, Jörg Petersen2, Hartwig Klinker3, Julian Schulze zur Wiesch4, Holger Hinrichsen5, Thomas Discher6, Lars Reinhardt7, Stefan Mauss8, Martina Müller-Schilling9, Claus Niederau10, Christoph Neumann-Haefelin11, Robert Thimme11, Christoph Berg12, Stefan Zeuzem1, Christoph Sarrazin1,13
1Medizinische Klinik1, Goethe-University Hospital, Frankfurt, 2Institute for Interdisciplinary Medicine IFI, Hamburg, 3Department of Internal Medicine II, University Hospital Würzburg, 4Department of Internal Medicine I, University Medical Center Hamburg-Eppendorf, 5Practice of Gastroenterology, Kiel, 6Department of Medicine II, Justus Liebig University Gießen, 7Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Göttingen, 8Practice of Gastroenterology, Düsseldorf,9Department of Internal Medicine I, University Hospital Regensburg, 10St. Josef-Hospital, Katholisches Klinikum Oberhausen, 11Department of Medicine II, University Hospital Freiburg, 12 Department of Gastroenterology, Hepatology, and Infectiology, University Hospital Tübingen, 13St. Josefs-Hospital, Wiesbaden, Germany
|
| |
|
|
|
|
|
